MSCM
BMRN icon

McElhenny Sheffield Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-92
Closed -$9.52K – 147
2022
Q4 		$9.52K Buy
+92
New +$8.64K ﹤0.01% 340

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

McElhenny Sheffield Capital Management's BMRN Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 92 shares — an estimated $9.52K sold.

McElhenny Sheffield Capital Management first reported a position in BMRN in Q4 2022 and held it in 1 quarter. The position peaked at $9.52K in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 92 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $9.52K.
  • McElhenny Sheffield Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's BioMarin Pharmaceuticals position peaked at $9.52K in Q4 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.